The recombinant shingles vaccine is associated with lower risk of dementia
Top Cited Papers
Open Access
- 25 July 2024
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 30 (10) , 2777-2781
Abstract
There is emerging evidence that the live herpes zoster (shingles) vaccine might protect against dementia. However, the existing data are limited and refer only to the live vaccine, which is now discontinued in the United States and many other countries in favor of a recombinant vaccine. Whether the recombinant shingles vaccine protects against dementia remains unknown. Here we used a natural experiment opportunity created by the rapid transition from the use of live to the use of recombinant vaccines to compare the risk of dementia between vaccine types. We show that the recombinant vaccine is associated with a significantly lower risk of dementia in the 6 years post-vaccination. Specifically, receiving the recombinant vaccine is associated with a 17% increase in diagnosis-free time, translating into 164 additional days lived without a diagnosis of dementia in those subsequently affected. The recombinant shingles vaccine was also associated with lower risks of dementia than were two other vaccines commonly used in older people: influenza and tetanus–diphtheria–pertussis vaccines. The effect was robust across multiple secondary analyses, and was present in both men and women but was greater in women. These findings should stimulate studies investigating the mechanisms underpinning the protection and could facilitate the design of a large-scale randomized control trial to confirm the possible additional benefit of the recombinant shingles vaccine.Keywords
Funding Information
- DH | National Institute for Health Research (NIHR203316, NIHR203316, NIHR203316)
- JDRF (4-SRA-2017-473-A-N)
- Wellcome Trust (203141/A/16/Z)
This publication has 34 references indexed in Scilit:
- Virus exposure and neurodegenerative disease risk across national biobanksNeuron, 2023
- Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infectionsBrain, Behavior, and Immunity, 2022
- Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccineCurrent Opinion in Immunology, 2019
- Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing RisksJAMA Cardiology, 2018
- Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsJAMA Internal Medicine, 2018
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial ResultsJAMA Cardiology, 2017
- The Propensity ScoreJAMA, 2015
- The use of bootstrapping when using propensity‐score matching without replacement: a simulation studyStatistics in Medicine, 2014
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effectsStatistics in Medicine, 2002